secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000882095-23-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q2 revenue $6.6B (+5%); EPS down to $0.83 on $525M legal charge; guidance raised ex-Veklury
--------------------------------------------------------------------------------

- Total product sales ex-Veklury up 11% to $6.3B; HIV sales up 9% to $4.6B, Biktarvy up 17% to $3.0B.
- Oncology sales up 38% to $728M; Trodelvy up 63% to $260M, Cell Therapy up 27% to $469M.
- GAAP diluted EPS $0.83 vs $0.91 YoY; non-GAAP EPS $1.34 vs $1.58; impact of $0.32 from $525M HIV antitrust litigation accrual.
- Full-year 2023 guidance: total product sales raised to $26.3-26.7B (prev $26.0-26.5B); ex-Veklury raised to $24.6-25.0B; Veklury lowered to ~$1.7B (prev ~$2.0B).
- GAAP EPS guidance lowered to $4.50-4.85 (prev $4.75-5.15); non-GAAP EPS lowered to $6.45-6.80 (prev $6.60-7.00).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/0000882095-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/gild-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000882095-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer